Mutation of ERBB2 Provides a Novel Alternative Mechanism for the Ubiquitous Activation of RAS-MAPK in Ovarian Serous Low Malignant Potential Tumors
Michael S. Anglesio(University of British Columbia), David D.L. Bowtell(The University of Melbourne), Lisa A. Simms(QIMR Berghofer Medical Research Institute), Jeremy M. Arnold(QIMR Berghofer Medical Research Institute), Anna DeFazio(The University of Sydney), Georgia Chenevix‐Trench(QIMR Berghofer Medical Research Institute), Joshy George(Jackson Laboratory), Sián Fereday(Peter MacCallum Cancer Centre), Bianca Locandro(Peter MacCallum Cancer Centre), Anna V. Tinker(BC Cancer Agency), Richard W. Tothill(The University of Melbourne), Raghwa Sharma(Royal Prince Alfred Hospital), Michael J. Birrer(University of Arkansas Medical Center), Nadia Traficante(The University of Melbourne), Peter Russell(The University of Sydney), Nicola Waddell(QIMR Berghofer Medical Research Institute)
Cited by 130
Related Papers
Mutations of the BRAF gene in human cancer
|Nature|2002|10.7k
Integrated genomic analyses of ovarian carcinoma
|Nature|2011|8.2k
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci
|Nature Genetics|2010|2.6k
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k
<i>ARID1A</i> Mutations in Endometriosis-Associated Ovarian Carcinomas
|New England Journal of Medicine|2010|1.7k